Jones Day advised Astellas Pharma Inc., a Japanese leader in the pharma industry, in its €800 million (US$852 million) acquisition of Ogeda SA, a privately owned Belgian drug discovery company.

In addition to M&A representation, Jones Day provided antitrust and intellectual property advice regarding this transaction.

For additional information about this matter, please contact: Thomas De Muynck, Christian B. Fulda
Client(s): Astellas Pharma Inc.
Practice(s): M&A, Antitrust & Competition Law, Intellectual Property, Tax, Life Sciences, Private Equity
Office(s): Brussels, Munich, Irvine, Washington, Frankfurt, Boston